AtriCure, Inc.
General ticker "ATRC" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $1.6B (TTM average)
AtriCure, Inc. does not follow the US Stock Market performance with the rate: -9.9%.
Estimated limits based on current volatility of 1.7%: low 34.73$, high 35.91$
Factors to consider:
- Earnings expected soon, date: 2026-07-23 amc
- Total employees count: 1350 (+3.8%) as of 2025
- US accounted for 26.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market acceptance, Market competition, Regulatory and compliance, Distributor dependency, Economic downturns and volatility
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [35.96$, 53.66$]
- 2026-12-31 to 2027-12-31 estimated range: [37.58$, 56.03$]
Financial Metrics affecting the ATRC estimates:
- Negative: with PPE of -368.5 at the end of fiscal year the price was very high
- Positive: -3.72 < Return on assets ratio (scaled to [-100,100]) of -1.72
- Positive: -5.34 < Operating profit margin, % of -1.74
- Positive: -0.03 < Operating cash flow per share per price, % of 2.96
- Positive: -9.70 < Industry operating profit margin (median), % of -3.62
- Positive: -4.39 < Investing cash flow per share per price, % of -0.75
- Positive: Inventory ratio change, % of -1.13 <= -0.75
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 1.67
Short-term ATRC quotes
Long-term ATRC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $399.25MM | $465.31MM | $534.53MM |
| Operating Expenses | $425.93MM | $505.32MM | $543.98MM |
| Operating Income | $-26.68MM | $-40.01MM | $-9.45MM |
| Non-Operating Income | $-3.16MM | $-3.66MM | $-0.72MM |
| Interest Expense | $6.92MM | $6.41MM | $5.88MM |
| R&D Expense | $73.92MM | $96.18MM | $99.21MM |
| Income(Loss) | $-29.85MM | $-43.67MM | $-10.16MM |
| Taxes | $0.59MM | $1.02MM | $1.28MM |
| Net Income(Loss)* | $-30.44MM | $-44.70MM | $-11.45MM |
| Stockholders Equity | $466.17MM | $460.97MM | $491.94MM |
| Inventory | $67.90MM | $75.33MM | $78.49MM |
| Assets | $613.93MM | $609.33MM | $654.18MM |
| Operating Cash Flow | $4.48MM | $12.20MM | $57.33MM |
| Capital expenditure | $42.00MM | $23.46MM | $9.05MM |
| Investing Cash Flow | $21.82MM | $30.23MM | $-14.55MM |
| Financing Cash Flow | $-0.03MM | $-3.60MM | $1.18MM |
| Earnings Per Share** | $-0.66 | $-0.95 | $-0.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.